Prenetics Global Limited (PRE)
| Market Cap | 267.07M +383.1% |
| Revenue (ttm) | 92.39M +201.7% |
| Net Income | -58.32M |
| EPS | -4.15 |
| Shares Out | 16.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 326,375 |
| Open | 15.76 |
| Previous Close | 15.90 |
| Day's Range | 15.06 - 16.32 |
| 52-Week Range | 5.07 - 23.63 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 30.50 (+92.19%) |
| Earnings Date | May 14, 2026 |
About PRE
Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions. Pren... [Read more]
Financial Performance
In 2025, Prenetics Global's revenue was $92.39 million, an increase of 201.72% compared to the previous year's $30.62 million. Losses were -$58.32 million, 26.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PRE stock is "Strong Buy." The 12-month stock price target is $30.5, which is an increase of 92.19% from the latest price.
News
Prenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with Davi...
Prenetics' IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
NEW YORK and MIAMI, May 07, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded...
Prenetics files to sell 2.36M Class A ordinary shares for holders
09:26 EDT Prenetics (PRE) files to sell 2.36M Class A ordinary shares for holders
Prenetics’ IM8 enters partnership with Superpower
Prenetics (PRE) Global announced a strategic partnership with Superpower. The partnership connects clinical-grade supplementation with comprehensive blood diagnostics, enabling an optimized testing lo...
Prenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and ...
Prenetics Global Transcript: The 38th Annual Roth Conference
Panelists from leading wellness and consumer brands discussed the importance of authentic influencer partnerships, emphasizing that genuine product use, equity alignment, and scientific validation drive long-term success. Data-driven tracking, multi-year deals, and a mix of macro and micro-influencers were highlighted as best practices.
Prenetics Global Transcript: The 38th Annual Roth Conference
IM8 has rapidly scaled to $100 million ARR in under a year by focusing on a unique all-in-one supplement, leveraging celebrity ambassadors, and a robust direct-to-consumer model. Strong retention, global reach, and aggressive digital marketing—powered by AI—support ambitious growth targets and new product launches in 2026.
Prenetics Global Transcript: Sidoti March Small-Cap Virtual Conference
IM8 drove explosive growth, reaching $120 million ARR in its first year and fueling a strategic focus on global DTC expansion. With robust liquidity, premium products, and strong ambassador partnerships, the brand projects $180–$200 million revenue in 2026 and aims for profitability by Q4 2027.
Prenetics initiated with a Buy at Lake Street
Lake Street initiated coverage of Prenetics (PRE) with a Buy rating and $29 price target Having divested three non-core assets, ACT Genomics, Europa, and its remaining stake in Insighta, Prenetics
Prenetics authorizes $40M share repurchase program
Prenetics (PRE) Global announced that its Board of Directors has authorized a share repurchase program of up to $40,000,000 over a 12-month period. Danny Yeung, CEO of Prenetics, commented: “We
Prenetics announces executive open market share purchases
Prenetics (PRE) Global announced that members of its executive leadership team have executed a second round of open market purchases of Prenetics common stock during the week of February 23
Prenetics announces launch of Daily Ultimate Essentials PRO
Prenetics (PRE) Global announced the launch of Daily Ultimate Essentials PRO. Alongside the reformulated product, Prenetics is also introducing two new flavours – Mango + Passionfruit and Lemon + Oran...
Prenetics Global Earnings Call Transcript: Q4 2025
Record 2025 revenue of $92.4M, up 480% year-over-year, driven by IM8's explosive growth and global expansion. Strategic divestitures strengthened liquidity to $171M with no debt. 2026 guidance targets $180M-$200M IM8 revenue and 60% gross margin, with profitability expected by Q4 2027.
Prenetics completes $70M Insighta sale to Tencent
Prenetics Global (PRE) announced the completion of the sale of its 35% equity interest in Insighta to Tencent (TCEHY) for total cash consideration of $70M. The transaction provides a substantial
Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity
Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced on February 18, 2026 NEW YORK, F...
Prenetics reports Q4 EPS ($1.77) vs. ($1.01) last year
Reports Q4 revenue $36.56M, consensus $33.43M. Danny Yeung, CEO, commented: “2025 was a defining year for Prenetics (PRE)-one in which we proved both the strength and scalability of IM8’s business
Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and l...
Prenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors
Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Lim...
Prenetics completes $70M Insighta Sale to Tencent
Prenetics Global (PRE) announced the completion of the sale of its 35% equity interest in Insighta to Tencent (TCEHY) for total cash consideration of $70M. The transaction provides a substantial
Prenetics announces Formula 1’s Ollie Bearman as newest Global Ambassador
Prenetics (PRE) Global announced Formula 1 Ollie Bearman as its newest Global Ambassador and a shareholder. This partnership marks another milestone for IM8 as it “continues to capture interest and
Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced...
Prenetics initiated with a Buy at Roth Capital
Roth Capital analyst George Kelly initiated coverage of Prenetics (PRE) with a Buy rating and $36 price target The company has “struggled to find its footing” after completing its business
Prenetics Global Transcript: Sidoti Micro-Cap Virtual Investor Conference
IM8, co-founded with David Beckham, has become the fastest-growing supplement brand, reaching $120 million ARR in under a year and projecting $180–$200 million revenue for 2026. With strong financials, global expansion, and high-profile ambassadors, the company is positioned for continued rapid growth.
Prenetics completes sale of its 3PL distribution business
Prenetics (PRE) Global announced that it has completed the sale of its 3PL distribution business operated by its subsidiary, Europa Sports Partners. The all-stock transaction is valued at up to
Prenetics provides update on voluntary warrant exchange program
Prenetics (PRE) Global announced an update to its previously announced voluntary warrant exchange program. In connection with the Company’s prior financing round in October 2025, 2,722,642 Class A ord...